Skip to main content
Clinical Trials/NCT05513417
NCT05513417
Enrolling by Invitation
N/A

Digital Care Programs for Female Pelvic Health: a Large-scale, Multi-disorder, Observational Study

Sword Health, SA1 site in 1 country50,000 target enrollmentAugust 29, 2022

Overview

Phase
N/A
Intervention
Not specified
Conditions
Pelvic Floor Disorders
Sponsor
Sword Health, SA
Enrollment
50000
Locations
1
Primary Endpoint
Pelvic Floor Impact Questionnaire - short form 7 (PFIQ-7)
Status
Enrolling by Invitation
Last Updated
last year

Overview

Brief Summary

The purpose of this study is to create a research repository, composed of data collected in the course of digital care programs for pelvic health conditions by SWORD Health/Bloom to individuals undergoing those programs.

This will allow the investigators to observe the acceptance, engagement and outcomes of programs using this approach in the treatment of multiple pelvic health disorders.

Detailed Description

This patient registry was designed as a research repository, composed of data collected in the course of digital care programs for pelvic health conditions by SWORD Health/Bloom to individuals undergoing those programs. This data will allow the researchers to: 1. Assess the adoption, engagement and feasibility of digital care programs for pelvic musculoskeletal disorders and pelvic health; 2. Assess the results of digital care programs and compare the costs with the benefits obtained; 3. Correlate the results with patient's demographic and clinical profiles; 4. Examine the impact of mental health and the behavioral modification components of Bloom's interventions on disease markers, comorbidities, and productivity; 5. Increase the knowledge on several pelvic musculoskeletal disorders, namely how they progress and respond to digital care programs; 6. Develop new or improved tools to assist clinicians in the management of these disorders and in helping people achieve better pelvic health The primary outcome will be the evolution of the participant's condition along the program. Depending on the condition, primary and secondary outcome measures vary, but the registry will include, in all cases, a complete characterisation of the participant's pelvic health status, as well as the periodic assessment of: a) performance indicators (through condition-specific tests); b) patient-reported outcomes (obtained using internationally validated pathology-specific questionnaires); c) pain levels; d) compliance; e) patient satisfaction

Registry
clinicaltrials.gov
Start Date
August 29, 2022
End Date
December 2032
Last Updated
last year
Study Type
Observational
Sex
Female

Investigators

Sponsor
Sword Health, SA
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Over 18 years old;
  • Signs/symptoms consistent with an acute (\<12 weeks) or chronic (\>12 weeks) abdominopelvic condition without signs/symptoms indicating underlying disease states that require immediate referral for medical management OR recovering from pelvic surgery with indication from their surgeon to engage in a pelvic physical therapy program
  • Able to understand study procedures and willing to provide informed consent.

Exclusion Criteria

  • Health condition (cardiac, respiratory, neurological, immune) condition incompatible with at least 20 minutes of light to moderate exercise if not cleared by a physician to engage in an exercise program
  • Bone fractures or other musculoskeletal conditions in which mobilization of the segment or joint is contra-indicated
  • Rapidly progressive and new in onset neurological complaints if not cleared by a physician to engage in an exercise program; or signs of acute, serious neurologic compromise
  • Active cancer diagnosis or receiving treatment for cancer if not cleared by a physician to engage in an exercise program
  • Signs/symptoms consistent with inflammatory bowel diseases (Crohn's, ulcerative colitis, etc.)
  • Signs/symptoms consistent with an active pelvic infection
  • Aphasia, dementia or any other psychiatric comorbidity that interferes with the use of the medical device
  • Complicated or high-risk pregnancy
  • Hemodynamic instability
  • Significant trauma to the area of pain within the last 12 weeks and functional incapacity and not cleared by a physician to engage in an exercise program

Outcomes

Primary Outcomes

Pelvic Floor Impact Questionnaire - short form 7 (PFIQ-7)

Time Frame: Baseline, then 3, 5 and 10 weeks after program initiation, and then at 6, 12 and 24 months after enrolment

The PFIQ-7 consists of 7 questions that need to be answered 3 times each considering symptoms related to the bladder or urine, vagina or pelvis, and bowel or rectum and their effect on function, social health, and mental health in the past 3 months. The responses for each question range from "not at all" (0) to "quite a bit" (3). To get scale scores, the mean of each of the 3 scales is individually calculated, which ranges from 0-3, this number is then multiplied by 100 and then divided by 3. The scale scores are then added together to get the total PFIQ-7 score, which ranges from 0-300. A lower score means there is a lesser effect on quality of life.

Self-reported symptom level

Time Frame: Baseline, and then at regular intervals (after 9, 15 and 30 sessions) after program initiation, and then at 6, 12 and 24 months after enrolment

Change over time in clinical outcomes common to all conditions measured through a 0-10 Pain Numerical Rating Scale referring to the previous 7 days. Higher scores mean more symptoms.

Secondary Outcomes

  • Self-reported consumption of painkillers(aseline, then 3, 5 and 10 weeks after program initiation, and then at 6, 12 and 24 months after enrolment)
  • Self-reported fatigue (VAS)(aseline, then 3, 5 and 10 weeks after program initiation, and then at 6, 12 and 24 months after enrolment)
  • Self-reported symptom level (VAS)(aseline, then 3, 5 and 10 weeks after program initiation, and then at 6, 12 and 24 months after enrolment)
  • Depression(aseline, then 3, 5 and 10 weeks after program initiation, and then at 6, 12 and 24 months after enrolment)
  • Anxiety(aseline, then 3, 5 and 10 weeks after program initiation, and then at 6, 12 and 24 months after enrolment)
  • Work productivity and absenteeism(aseline, then 3, 5 and 10 weeks after program initiation, and then at 6, 12 and 24 months after enrolment)
  • Self-reported intent to seek additional healthcare services(aseline, then 3, 5 and 10 weeks after program initiation, and then at 6, 12 and 24 months after enrolment)

Study Sites (1)

Loading locations...

Similar Trials